RTTNews BiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 19:42:26时区推断·⟳ 抓取 19:47:36·⚡ 决策 07-30 19:51:39 +4m03s·89.2 天前
辉瑞LITFULO在非节段型白癜风两项III期研究达到共同主要终点
事件对辉瑞（PFE.US）方向为正，但仍只是topline III期读出和拟申报监管，尚非获批或商业化落地。
📄 原文RTTNews Biotech↗ 原文
Pfizer Reports Positive Phase 3 Results For LITFULO In Nonsegmental Vitiligo
Pfizer Inc. (PFE) announced topline results from two pivotal Phase 3 trials of LITFULO in patients with nonsegmental vi…
不做 辉瑞（PFE.US）
III期阳性方向正确但仍未获批，且白癜风市场相对辉瑞626亿美元收入和1433亿美元市值太小，盘前也未正向确认，不做追多。
不做 Incyte（INCY.US）
辉瑞LITFULO对Opzelura有远期竞争压力，但不是已获批上市的即时替代；Incyte自身povorcitinib白癜风III期阳性且Opzelura基础销售增长，做空催化强度不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 辉瑞正式披露LITFULO两项非节段型白癜风III期研究达到共同主要终点，并计划递交全球监管申请。
- RTTNews转发辉瑞LITFULO白癜风III期阳性结果，并附带辉瑞盘前价格信息。市场反应:档案显示辉瑞盘前约25.00美元，较前收跌0.64%。
- 2026-07-30 07:47 ET市场反应Futu/stock_quote非一手行情工具显示辉瑞上一交易日收25.15美元、当日变动-0.40%；Incyte上一交易日收127.10美元、当日变动-2.18%，未见因本事件形成明确可交易重定价。市场反应:PFE.US未出现正向盘前确认，INCY.US此前更多受自身财报和管线预期驱动。
关键理由
- 事件对辉瑞（PFE.US）方向为正，但仍只是topline III期读出和拟申报监管，尚非获批或商业化落地。
- 全球白癜风治疗市场2026年约19.4亿美元；即使LITFULO获批后拿到约20%份额，潜在年销售约4亿美元，仅约为辉瑞2025年收入626亿美元的0.6%、当前市值1433亿美元的0.3%。
- 对Incyte（INCY.US）的Opzelura存在远期竞争读出，但Incyte已有自研口服povorcitinib白癜风III期阳性，且Opzelura基础销售仍在增长，做空强度不足。
主要风险
- 若后续完整疗效数据明显优于Incyte/AbbVie同类口服JAK方案，或监管给出快速审评路径，辉瑞的皮肤科管线期权价值可能被重新上修。
- LITFULO为口服JAK/TEC抑制剂，安全性黑框和医保准入会决定真实商业化速度，当前topline信息不足以估算高置信销售爬坡。
反向证据
- 做多前查反向 · 来源 web · 日期 2026 · 影响 weakens
辉瑞2025年收入626亿美元、当前市值约1433亿美元，而白癜风治疗市场2026年约19.4亿美元，新增适应症量级不足以支撑PFE短线追多。
检索:Pfizer LITFULO vitiligo Phase 3 revenue market size Pfizer 2025 revenue 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-04-28 · 影响 weakens
Incyte自有口服povorcitinib白癜风III期阳性且Opzelura基础需求增长，辉瑞读出不是足够强的公司级净利空。
检索:Incyte povorcitinib positive phase 3 nonsegmental vitiligo 2026 oral systemic 原文 ↗ - 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中可改变方向的LITFULO销售量级或辉瑞短线重估证据。
检索:Pfizer LITFULO vitiligo phase 3 revenue Opzelura Incyte competitive impact
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,268 字
Pfizer Inc. (PFE) announced topline results from two pivotal Phase 3 trials of LITFULO in patients with nonsegmental vitiligo, showing that the studies met their co-primary endpoints with significant improvements in facial and total body repigmentation compared to placebo at Week 52.
Vitiligo is a chronic autoimmune disease in which the immune system attacks melanin-producing cells, leading to a loss of pigment and visible white patches on the skin. Nonsegmental vitiligo (NSV), the most common form, can affect highly visible areas such as the face, neck, and hands, often impacting patients' quality of life well beyond cosmetic concerns.
The Phase 3 program, the largest to date evaluating an oral systemic therapy for NSV included the TRANQUILLO study in patients aged 12 years and older and TRANQUILLO 2 in adults. Both the 50 mg and 100 mg doses of LITFULO demonstrated clinically meaningful improvements over placebo on the Vitiligo Area Scoring Index (VASI).
Michael Vincent, M.D., Ph.D., Chief Inflammation & Immunology Officer, Pfizer, said LITFULO was internally discovered and has a unique mechanism of action targeting TEC family kinases and JAK3. He noted that the positive results build on Pfizer's dermatology expertise and prior experience with LITFULO in alopecia areata, reinforcing confidence in its potential as a new oral systemic treatment option for adults with NSV.
Based on these findings, Pfizer intends to submit global regulatory filings for LITFULO as a potential new oral systemic therapy in NSV for adults. If approved, it could become the first oral systemic treatment designed to restore and maintain skin pigmentation in adults living with the condition.
PFE has traded between $23.11 and $28.75 over the past year. The stock closed Wednesday's trading at $25.15, down 0.40%. In pre-market trading the stock is at $25.00, down 0.64%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 30, 2026 04:24 ET The August 2026 FDA calendar features several important PDUFA decisions that could influence the biotech sector, healthcare innovation, and investor sentiment. In this video, we break down five major FDA decisions expected in August 2026, including the therapies, companies, and diseases under review:
Vitiligo is a chronic autoimmune disease in which the immune system attacks melanin-producing cells, leading to a loss of pigment and visible white patches on the skin. Nonsegmental vitiligo (NSV), the most common form, can affect highly visible areas such as the face, neck, and hands, often impacting patients' quality of life well beyond cosmetic concerns.
The Phase 3 program, the largest to date evaluating an oral systemic therapy for NSV included the TRANQUILLO study in patients aged 12 years and older and TRANQUILLO 2 in adults. Both the 50 mg and 100 mg doses of LITFULO demonstrated clinically meaningful improvements over placebo on the Vitiligo Area Scoring Index (VASI).
Michael Vincent, M.D., Ph.D., Chief Inflammation & Immunology Officer, Pfizer, said LITFULO was internally discovered and has a unique mechanism of action targeting TEC family kinases and JAK3. He noted that the positive results build on Pfizer's dermatology expertise and prior experience with LITFULO in alopecia areata, reinforcing confidence in its potential as a new oral systemic treatment option for adults with NSV.
Based on these findings, Pfizer intends to submit global regulatory filings for LITFULO as a potential new oral systemic therapy in NSV for adults. If approved, it could become the first oral systemic treatment designed to restore and maintain skin pigmentation in adults living with the condition.
PFE has traded between $23.11 and $28.75 over the past year. The stock closed Wednesday's trading at $25.15, down 0.40%. In pre-market trading the stock is at $25.00, down 0.64%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 30, 2026 04:24 ET The August 2026 FDA calendar features several important PDUFA decisions that could influence the biotech sector, healthcare innovation, and investor sentiment. In this video, we break down five major FDA decisions expected in August 2026, including the therapies, companies, and diseases under review:
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。